Curated News
By: NewsRamp Editorial Staff
November 04, 2025
Lung Cancer Screening Crisis: Low Rates Despite Deadly Impact
TLDR
- Early lung cancer screening provides a survival advantage with 5-year rates reaching 26.6%, giving proactive individuals better health outcomes than those who delay testing.
- The American Lung Association reports low screening rates despite lung cancer causing 20% of US cancer deaths, while survival improved from 2015-2019 through advanced treatments.
- Increased lung cancer screening and novel treatments from companies like Calidi Biotherapeutics can save lives and reduce the burden of this deadly disease on families.
- Lung cancer survival rates have climbed to 26.6% over five years thanks to medical advances, yet most eligible Americans miss early detection opportunities.
Impact - Why it Matters
This news matters because lung cancer remains the leading cause of cancer deaths in the United States, yet most eligible individuals aren't getting screened. Early detection through screening can dramatically improve survival rates and treatment outcomes. The low screening rates represent a massive missed opportunity to save lives and reduce healthcare costs. As new treatments emerge from companies like Calidi Biotherapeutics, the importance of early detection becomes even more critical - advanced therapies work best when cancer is caught early. This affects not only current at-risk individuals but also sets the stage for future public health strategies that could prevent thousands of unnecessary deaths annually.
Summary
A startling report from the American Lung Association reveals that only a tiny fraction of eligible Americans undergo lung cancer screening, despite lung cancer accounting for 20% of all cancer deaths in America. This critical gap in preventive healthcare persists even as lung cancer remains one of the deadliest forms of cancer, highlighting a significant public health challenge that demands immediate attention from healthcare providers, policymakers, and at-risk populations.
While screening rates remain alarmingly low, there is encouraging news on the treatment front. Survival rates for lung cancer have registered an uptick in recent years, with the five-year survival rate now standing at 26.6% according to data from 2015 to 2019. This improvement reflects significant advances in research and novel treatments, with innovative companies like Calidi Biotherapeutics Inc. (NYSE American: CLDI) actively developing new therapeutic approaches to build on these promising trends and further improve patient outcomes.
The report underscores the urgent need for increased awareness and accessibility of lung cancer screening programs, particularly given the substantial progress being made in treatment options. As the medical community continues to develop more effective therapies, ensuring that patients are diagnosed early through proper screening becomes increasingly crucial. The combination of early detection through improved screening rates and advanced treatments from companies focused on building on current medical breakthroughs could dramatically transform lung cancer outcomes in the coming years.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Lung Cancer Screening Crisis: Low Rates Despite Deadly Impact
